AusBiotech says new body will replace current function of Innovation Australia in 2016; rounds up 2015

22 December 2015
2019_biotech_test_vial_discovery_big

AusBiotech, the representative body for the Australian biotech industry, said as part of the National Innovation and Science Agenda (NISA), a new independent board, Innovation and Science Australia (ISA), will replace the current function of Innovation Australia in 2016 and will be responsible for strategic coordination and advising government on all science, research and innovation matters.

The industry body, in a warp up statement for 2015 said, ISA will be chaired by Bill Ferris, with Australia’s next chief scientist, Dr Alan Finkel, as deputy chairman. One of the ISA’s first responsibilities will be to review the R&D Tax Incentive, to sharpen its focus on encouraging additional R&D spend.

AusBiotech said it will seek to participate in the review, as the industry organization has with the previous reviews if the R&D Tax Incentive. AusBiotech noted that there is no mention as yet of abandoning the 1.5% cut to the R&D Tax Incentive, which remains on the notice paper.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology